17.08.2022

Artikel Nummer: 41661
Investing in life sciences environment
Singapore-headquartered ESR and its JV partner have acquired a life sciences R&D business park for RMB 268 million (USD 40 million) in Zhangjiang, Shanghai (China). Formerly known as Zhangjiang NEO, the unit of almost 9,000 sqm consists of two blocks with Pharmaceutical R&D lab and office space. Over 90% of the tenants (in terms of leased GFA) are major biopharmaceutical companies.
The life sciences R&D business park is located at Shanghai Zhangjiang Hi-Tech Development Zone (Zhangjiang Pharma Valley Phase II), a R&D cluster comprising more than 600 life sciences companies, 150 R&D institutions, and seven large pharmaceutical companies. The business park is a 25-minute ride to Pudong International Airport. (sh)